Diatranz Otsuka

Diatranz Otsuka is a biotechnology company specializing in xenotransplantation and regenerative medicine, specifically for the treatment of Type 1 diabetes. Originally formed as a joint venture between Living Cell Technologies and Otsuka Pharmaceutical Factory, the company focuses on the development of DIABECELL, an encapsulated porcine islet cell therapy. The proprietary encapsulation technology is designed to protect the transplanted cells from the recipient's immune system, potentially eliminating the need for chronic immunosuppression. Since becoming a wholly-owned subsidiary of Otsuka, the company has continued to leverage its expertise in cell-based therapies to address unmet needs in metabolic diseases.